• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

Opinion
Video

Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Christopher Bunick, MD, PhD

Associate Professor, Dermatologist

Yale University

Middlebury, Connecticut

Ruth Ann Vleugels, MD, MPD, MBA

Vice-Chair of Academic Affairs

Department of Dermatology at Brigham and Women’s Hospital

Boston, Massachusetts

Program Description: Experts discuss the results of multiple studies analyzing the incident rates and safety of Janus Kinase (JAK) inhibitors in the treatment of atopic dermatitis (AD).

Segment Description: Christopher Bunick, MD, PhD, presents the conclusions and major take-aways of the study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).

Related Videos
© 2024 MJH Life Sciences

All rights reserved.